Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 15/20 | 0.65 |
| ▸ | RIPK3 | Q9Y572 | 10/20 | 0.60 |
| ▸ | RIPK1 | Q13546 | 6/20 | 0.60 |
| ▸ | RIPK2 | O43353 | 5/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | LCK | P06239 | 1/20 | 0.52 |
| ▸ | KIT | P10721 | 1/20 | 0.52 |
| ▸ | KDR | P35968 | 1/20 | 0.52 |
| ▸ | FLT3 | P36888 | 1/20 | 0.52 |
| ▸ | AXL | P30530 | 3/20 | 0.51 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.51 |
| ▸ | MERTK | Q12866 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1137058 | 0.94 | MET (0.57) | METRIPK3RIPK1RIPK2CYP3A4 | |
| SCHEMBL1137557 | 0.91 | MET (0.79) | METRIPK3RIPK1RIPK2CYP3A4 | |
| SCHEMBL16241072 | 0.89 | MET (0.63) | METRIPK3RIPK1RIPK2CYP3A4 | |
| SCHEMBL12350029 | 0.87 | MET (0.67) | METRIPK3RIPK1RIPK2CYP3A4 | |
| SCHEMBL1137504 | 0.84 | MET (0.69) | METRIPK3RIPK1RIPK2CYP3A4 | |
| SCHEMBL1269377 | 0.83 | MET (0.58) | METRIPK3RIPK1RIPK2CYP3A4 | |
| SCHEMBL12350064 | 0.83 | MET (0.58) | METLCKKITKDRFLT3 | |
| SCHEMBL16058783 | 0.82 | AXL (0.71) | METRIPK3RIPK1RIPK2FLT3 | |
| SCHEMBL16060855 | 0.80 | AXL (0.59) | METRIPK3RIPK1RIPK2AXL | |
| SCHEMBL4818940 | 0.80 | MET (0.79) | METRIPK3RIPK1CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989477-B2 | Monocyclic heterocycles as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-08-02 | — | — | US | disclosed |
| US-7989477-B2 | Monocyclic heterocycles as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-08-02 | — | — | US | disclosed |
| EP-1737451-B1 | MONOCYCLIC HETEROCYCLES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2011-02-23 | — | — | EP | disclosed |
| EP-1737451-B1 | MONOCYCLIC HETEROCYCLES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2011-02-23 | — | — | EP | disclosed |
| US-20100183606-A1 | MONOCYCLIC HETEROCYCLES AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-07-22 | — | — | US | disclosed |
| US-20100183606-A1 | MONOCYCLIC HETEROCYCLES AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-07-22 | — | — | US | disclosed |
| US-7714138-B2 | Monocyclic heterocycles as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-05-11 | — | — | US | disclosed |
| US-7714138-B2 | Monocyclic heterocycles as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-05-11 | — | — | US | disclosed |
| US-7714138-B2 | Monocyclic heterocycles as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-05-11 | — | — | US | disclosed |
| US-20090054436-A1 | MONOCYCLIC HETEROCYCLES AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-02-26 | — | — | US | disclosed |
| US-20090054436-A1 | MONOCYCLIC HETEROCYCLES AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-02-26 | — | — | US | disclosed |
| US-20090054436-A1 | MONOCYCLIC HETEROCYCLES AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-02-26 | — | — | US | disclosed |
| US-7459562-B2 | Monocyclic heterocycles as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-02 | — | — | US | disclosed |
| US-7459562-B2 | Monocyclic heterocycles as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-02 | — | — | US | disclosed |
| US-20050245530-A1 | Monocyclic heterocycles as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054436-A1 | MONOCYCLIC HETEROCYCLES AS KINASE INHIBITORS | CDK2, MAP3K19, CDK1 | MET 162/4885RIPK3 489/4885RIPK1 558/4885 |
| US-20050245530-A1 | Monocyclic heterocycles as kinase inhibitors | CDK2, MAP3K19, CDK1 | MET 162/4885RIPK3 489/4885RIPK1 558/4885 |
| US-20100183606-A1 | MONOCYCLIC HETEROCYCLES AS KINASE INHIBITORS | CDK2, MAP3K19, CDK1 | MET 162/4885RIPK3 489/4885RIPK1 558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.